Ocugen (OCGN) Other Non Operating Income (2014 - 2026)
Ocugen's (OCGN) quarterly Other Non Operating Income came in at -$150000.0 in Q1 2026, down 330.77% YoY from $65000.0 in Q1 2025, and down 131.45% on a QoQ basis from $477000.0 in Q4 2025.
Ocugen (OCGN) Other Non Operating Income (2014 - 2026) Analysis & Trends
Ocugen (OCGN) has 11 years of Other Non Operating Income data on file, last reported at -$150000.0 in Q1 2026.
- Quarterly Other Non Operating Income fell 330.77% year-over-year to -$150000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$927000.0 (down 496.15% YoY) and the FY2025 annual result came in at -$664000.0, down 574.29% from the prior year.
- Other Non Operating Income declined to -$150000.0 in Q1 2026, from $477000.0 in the prior quarter.
- In the past five years, Other Non Operating Income ranged from a high of $477000.0 in Q4 2025 to a low of -$1.3 million in Q3 2025.
- A 4-year average of -$108285.7 and a median of $15000.0 in 2022 frame the typical range for Other Non Operating Income.
- The widest YoY moves for Other Non Operating Income: up 211.76% in 2025, down 132000.0% in 2025.
- Tracing OCGN's Other Non Operating Income over 4 years: stood at $15000.0 in 2022, then surged by 920.0% to $153000.0 in 2024, then surged by 211.76% to $477000.0 in 2025, then slumped by 131.45% to -$150000.0 in 2026.
- The last three Other Non Operating Income figures came in at -$150000.0 (Q1 2026), $477000.0 (Q4 2025), and -$1.3 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Ocugen | 457.71 Mn | 357.61 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -2.38 Mn |
| Mar 31, 2026 | -150,000.00 |
| Dec 31, 2025 | 477,000.00 |
| Sep 30, 2025 | -1.32 Mn |
| Mar 31, 2025 | 65,000.00 |
| Dec 31, 2024 | 153,000.00 |
| Sep 30, 2024 | 1,000.00 |
| Mar 31, 2022 | 15,000.00 |
| Dec 31, 2021 | 336,000.00 |
| Sep 30, 2021 | -4,000.00 |
| Jun 30, 2021 | -332,000.00 |
| Mar 31, 2021 | -20,000.00 |
| Dec 31, 2019 | -32,507.00 |
| Sep 30, 2019 | -18.51 Mn |
| Jun 30, 2019 | -608,149.00 |
| Mar 31, 2019 | -416.00 |
| Dec 31, 2018 | 1.50 Mn |
| Sep 30, 2018 | 1.46 Mn |
| Jun 30, 2018 | -26,000.00 |
| Mar 31, 2018 | -24,000.00 |